Allergan (NYSE:AGN) is expected to report Q1 earnings Friday, April 30 before the market open, with a conference call scheduled for 9 am ET.
Analysts are looking for EPS of 60c on revenue of 1.11B. The consensus range is 58c-66c for EPS, and $1.07B-$1.18B for revenue, according to First Call. In early February the company gave Q1 EPS guidance of 57c-59c. At the time the EPS consensus estimate for Q1 was 68c. Botox sales may have strengthened as a result of the economic recovery and a rebound in discretionary consumer spending. Another positive for Q1 is seen coming from Latisse, a drug that has been found to enhance eyelash growth. Ophthalmic drugs should also be a positive driver for Allergan in Q1. Possible negative pressures this quarter may be seen coming from Dysport competing for Botox sales.
On April 19, Goldman Sachs upgraded Allergan to Conviction Buy from Neutral.